Psychiatric medications in pregnancy and lactation

Dr Bavi Vythilingum Division CL Psychiatry, Dept of Psychiatry UCT Rondebosch Medical Centre

Psychiatric disorders in pregnancy

   In SA 30 -40% of women have antenatal depression Decision to treat – benefit to mother vs risk to child More accurate – look at benefit to mother and child vs risk to mother and child

 “Would a physician tell a pregnant woman with epilepsy, ‘Stop your meds and ride out the seizures until you deliver’? Are the medications of pregnant women with mental illness somehow more “optional”?” Dr Helen Kim, MGH Center Mental Health for Women’s

Psychiatric medications in pregnancy and lactation

Prescribing principles in pregnancy and lactation

 Monotherapy  Lowest effective dose

SSRI’s

 First line pharmacotherapy  Citalopram, sertraline appear best tolerated  No long term behavioural effects

SSRI and PPHN

 Six published studies  – only three studies adequately powered.

3 studies – increased risk  Absolute risk cannot be determined,  BUT probably less than 1%.  Information does not support discontinuation or lowering the dose of the antidepressant.

Antidepressants and teratogenicity

      Several studies linking SSRI use to – – – Cardiac defects AHDH Autism Large database studies No face to face interview Multiple confounders – adequate power?

Qualitatively different cases vs control – Other drug use, higher rates FAS, older No control for effect parenting

Tricylic Antidepressants (TCA’s)

 No increased teratogenic risk  More adverse side effect profile – particularly postural hypotension – constipation – lethality in overdose  Generally used as second line agents.

Other antidepressants

 Venlafaxine, duloxetine, bupropion – Less data  – Probably safe MAOI’s – no data, avoid due to dietary restrictions, risk hypertension

Take Home Message

 Risk of teratogenecity  Absolute risk is not clear but appears to be small  Psychotherapy treatment of choice for perinatal depression  Weigh risk benefit ratio

Management of Bipolar Disorder during Pregnancy

 Should be by a psychiatrist  Teratogenic risk – Lithium Ebstein’s anomaly 1-5% (vs 0.5 – 1% risk) – – – Na Valproate NTD, other anomalies, 3x vs other antiepileptics, 4x general population Carbamazepine 1% risk neural tube defects (vs 0.1% risk) Lamotrigine limited evidence, cleft palate

Second generation antipsychotics

 Attractive – No described teratogenicity – Mood stabilisers  Metabolic side effects – Boden 2012 – gestational diabetes adjusted OR, 1.77 [95% CI, 1.04-3.03] – Higher risk SGA infant - confounders

Medication Summary

 Lithium – safest  Lamotrigine, atypicals  Individualise for patient – appears safe  Adequate risk counselling

Patient falls pregnant on medication

 DO NOT STOP MEDICATION  Minimal decrease in risk of defects vs high risk relapse  Continue meds at lowest effective dose  Early US and anomaly scan  FOLATE

Medication through pregnancy

 Changing maternal blood volumes  Increase doses during pregnancy – Lithium – levels monthly first 2 trimesters, every fortnight thereafter – Valproate, CBZ – guided clinically, checking levels every 2 -3 months useful

Delivery

 Liaise closely with obstetrician  Hospital  Adequate pain control   IV line up Stop lithium, benzo’s at onset labour, recommence post delivery after checking level  High risk for post natal depression/psychosis

Benzodiazepines

   Small increased risk for cardiac/oral cleft malformations with first-trimester exposure.

Neonatal toxicity (“floppy infant syndrome”) /withdrawal Avoid in the first trimester,late in the third trimester

Benzodiazepines II

 To minimize neonatal withdrawal, gradually taper the mother’s benzodiazepine before delivery – – Taper 3 to 4 weeks before the due date and discontinue at least 1 week before delivery.

If benzodiazepines cannot be tapered   use a short acting agent advise the mother to discontinue benzodiazepine use as soon as she thinks she is going into labour.

Medication

    Generally SSRI’s and TCA’s safe in pregnancy and breastfeeding Antipsychotics – reasonably safe Mood stabilisers – teratogenic risk ECT – option

Breastfeeding and Medication

 MOST WOMEN ON MEDS CAN BREASTFEED!!!!!

 Risk of child dying from diarrhoea, respiratory disease, malnutrition higher than medication side effects  Breastfeeding, bedsharing mothers get more sleep  Case by case basis

Breastfeeding and Medication

 Lowest effective maternal dose  All meds excreted into breastmilk  Watch baby – Jaundice  – Excessive sleepiness Pre term – probably best not to breastfeed

Breastfeeding and medication II

 Antidepressants – generally safe  Antipsychotics – Infant sedation – Neonatal EPSE

Breastfeeding and medication III

 Mood stabilisers – All present problems – Consider risk benefit carefully  Lithium – Maternal hydration important  Anticonvulsant class – Rashes

Eglonyl?

 Sulpiride  Antipsychotic with theoretical mood elevation properties at low doses  Side effect of increasing milk supply  Sedating  NOT an effective antidepressant

Pregnancy and lactation summary

 All medications present risk – some higher than others  Weigh risk benefit ratio  PNDSA www.pndsa.org

– 0828820072 – [email protected]

 Otispregnancy.org

 www.infantrisk.com

 In general, women do not use psychotropic medications during pregnancy without good reason.  They educate themselves, struggle with treatment options, and in many cases stop medication, relapse, and then restart it when they become ill.  Being pregnant and giving birth to a child is an exhausting physical and emotional experience. A woman is vulnerable and deserves support, not shaming.